Bristol Myers Squibb shared on LinkedIn:
“Today we reported our Q2 earnings results and raised our 2026 full-year outlook, marking an excellent quarter driven by disciplined execution.
We saw continued strong performance from our Growth Portfolio, which grew 15% and underscores the progress we’re making to fuel durable, long-term growth. At the same time, we’re advancing a broad and differentiated pipeline while maintaining financial flexibility to invest in the highest-value opportunities for patients and shareholders.
Read more, including important cautionary statements about forward-looking information.”
Adam Lenkowsky, Executive Vice President, Chief Commercial Officer at Bristol Myers Squibb, added on LinkedIn:
“I am proud of our Bristol Myers Squibb team for delivering another strong quarter in Q2. Sales in the second quarter marked the highest quarterly sales in our company’s history. This performance reflects the unwavering dedication, focus, and drive of the entire team as we work to bring our transformational medicines to patients.
We achieved several important regulatory milestones this quarter. We continued to advance our CELMoD portfolio with positive Phase 3 results for mezigdomide in multiple myeloma and FDA acceptance of our New Drug Application. Looking ahead, we are excited about the August 17 PDUFA date for iberdomide and are ready for the launch of this important medicine, which has the potential to be the first commercialized CELMoD.
We are also making strong progress with our innovative pipeline, with seven pivotal data readouts expected through the end of the year that will help shape the next chapter of growth and innovation at BMS.
Thank you to all my BMS colleagues for your dedication and commitment. Our performance this quarter reinforces the strength of our strategy, the value of our innovative portfolio, and-most importantly-the talent, dedication, and tireless efforts of our teams around the world. It is an exciting time for Bristol Myers Squibb, and the foundation we have built positions us well to continue driving innovation and delivering meaningful impact for patients.”